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ABSTRACT
Background For the clinical management of
adrenocortical neoplasms it is crucial to correctly
distinguish between benign and malignant tumours. Even
histomorphologically based scoring systems do not allow
precise separation in single lesions, thus novel
parameters are desired which offer a more accurate
differentiation. The tremendous potential of microRNAs
(miRNAs) as diagnostic biomarkers in surgical pathology
has recently been shown in a broad variety of tumours.
Methods In order to elucidate the diagnostic impact of
miRNA expression in adrenocortical neoplasms, a cohort
of 20 adrenocortical specimens including normal adrenal
tissue (n¼4), adrenocortical adenomas (ACAs) (n¼9),
adrenocortical carcinomas (ACCs) (n¼4) and metastases
(n¼3) was analysed using TaqMan low density arrays to
identify speciﬁc miRNA proﬁles in order to distinguish
between benign and malignant adrenocortical lesions.
Results were validated in a validation cohort (n¼16).
Results Concerning the differential diagnosis of ACAs
and ACCs, 159 out of 667 miRNAs were up- and 89
were down-regulated in ACAs. Using real-time PCR
analysis of three of the most signiﬁcantly expressed
single key miRNAs allowed separation of ACAs from
ACCs. ACCs exhibited signiﬁcantly lower levels of miR-
139-3p (up to 8.49-fold, p<0.001), miR-675 (up to
23.25-fold, p<0.001) and miR-335 (up to 5.25-fold,
p<0.001). A validation cohort of 16 specimen with
known Weiss score showed up-regulation of miR-335
and miR-675 in the majority of cases with probable
malignant course, although overlapping values exist.
Conclusion miRNA proﬁling of miR-675 and miR-335
helps in discriminating ACCs from ACAs. miRNA analysis
may indicate malignant behaviour in cases with
indeterminate malignant potential.
INTRODUCTION
MicroRNAs (miRNAs) are a class of recently
discovered small RNA molecules that regulate the
expression of genes at the translational level.
1 2 The
understanding of these tiny RNA molecules is
rather limited, but studies indicate that miRNA-
mediated gene regulation is likely to play key roles
in human development, cellular differentiation and
oncogenesis. MiRNAs are endogenously expressed
short non-coding RNAs with 18e25 nucleotides in
length capable of repressing protein translation
through binding to target messenger RNA
(mRNA). The single stranded miRNAs, derived
from miRNA duplex complexes, can associate with
the RNA-induced silencing complex (RISC)
3 and
cause the translational repression or cleavage of
these target mRNA sequences.
The discovery of the ﬁrst miRNAs in 1993
immediately stimulated research in the medical
ﬁeld, and the question arose as to what extent
miRNA analysis may be utilised in surgical
pathology. Recent research indicated that evalua-
tion of miRNA expression levels may substantially
contribute to the understanding of cancer devel-
opment, progression and treatment.
4 Analysis of
miRNA up- and down-regulation has been shown
to be useful to support the diagnosis in a broad
variety of lesions including, for example, endocrine
tumours from the thyroid gland.
5e10
Recently Giordano et al described a set of
miRNAs related to prognosis in adrenocortical
carcinoma (ACC).
11 Whereas the discrimination of
normal adrenal tissue and adrenocortical adenoma
(ACA) is usually not challenging to the pathologist,
the differential diagnosis of adrenocortical adenoma
from ACC is notoriously difﬁcult. ACC is a rare
tumour which accounts for less than 0.2% of all
human malignancies. Up to two-thirds of cases
have distant metastases at the time of diagnosis,
and the mortality exceeds 90% with a mean
survival of less than 30 months.
12 13 Unlike in other
malignancies, the diagnosis of ACC cannot be based
on simple morphological parameters. To overcome
the problem, distinct sets of histopathological
criteria for the discrimination of benign and
malignant adrenocortical neoplasm have been
proposed.
12 14 15 Nevertheless a clear separation of
these neoplasms remains impossible unless the
patient develops metastases. This is mainly due to
the fact that such scores are based on histo-
morphological features that are likely to suffer from
interobserver variation.
Little is currently known about the microRNA
expression proﬁle in adrenocortical tumours. In
a very recent paper several miRNAs are described to
be of diagnostic as well as prognostic value in ACAs
and ACCs,
16 indicating the potential value of
microRNA expression patterns in diagnostic
pathology. In order to further investigate the
miRNA expression proﬁles in adrenal tissue, we
performed miRNA analyses on a series of normal,
benign and malignant adrenocortical tissue to
analyse 667 human miRNA, followed by real-time
PCR based validation of miRNA expression of
single key miRNAs with potential diagnostic value
in discriminating ACC from ACA. In a third step
we compared miRNA expression levels of key
miRNAs with the Weiss score in a validation cohort.
< A supplement is published
online only. To view this ﬁle
please visit the journal online
(http://jcp.bmj.com).
1Institute of Pathology and
Neuropathology, University
Hospital of Essen, University of
Duisburg-Essen, Essen,
Germany
2Pathologisches Institut
Recklinghausen, Recklinhausen,
Germany
3Integrated Functional Genomics
(IFG), Interdisciplinary Center for
Clinical Research (IZKF),
University Hospital of Muenster,
Westfalian Wilhelms-University
of Muenster, Muenster,
Germany
4Department of Surgery and
Centre of Minimally Invasive
Surgery, Kliniken Essen-Mitte,
Essen, Germany
Correspondence to
Klaus J Schmitz, Institute of
Pathology and Neuropathology,
University Hospital Essen,
University of Duisburg-Essen,
Hufelandstrasse 55, Essen
45122, Germany;
schmitzies@versanet.de
Accepted 9 March 2011
Published Online First
6 April 2011
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
jcp.bmj.com/site/about/
unlocked.xhtml
J Clin Pathol 2011;64:529e535. doi:10.1136/jcp.2010.085621 529
Original articleMATERIAL AND METHODS
Patient material
Formaldehyde-ﬁxed parafﬁn-embedded tissue collection samples
examined in the years from 2001 to 2008 were retrieved from the
ﬁles of the Institute of Pathology and Neuropathology, Univer-
sity Hospital of Essen, University of Duisburg-Essen, German.
All cases selected were operated and seen for follow-up at the
Department of Surgery and Centre of Minimally Invasive
Surgery, Kliniken Essen-Mitte, Essen, Germany and the
Department of Transplantation and General Surgery, University
Hospital Essen, Essen, Germany. The test cohort comprised
normal adrenocortical tissue (n¼4) taken from nephrectomy
specimens, ACAs associated with Cushing syndrome (n¼5) and
associated with Conn syndrome (n¼4), ACCs (n¼4) and tissue
from metastases of ACCs (n¼3). The validation cohort
comprised 15 primary adrenocortical lesions and one lung
metastasis, all scored according to the criteria of Weiss et al.
15
The tumours for this study were reviewed by KJS. Tumour
classiﬁcation was performed according to the current WHO
classiﬁcation (2004).
13 All ACC cases of the test study demon-
strated at least three criteria associated with malignancy, for
example necrosis, capsular invasion, vascular invasion, increased
mitotic activity, signiﬁcant atypia and/or metastases
according the criteria proposed by Weiss et al.
15 Table 1
summarises clinicopathological data of all ACCs.
Tissue was retrieved from parafﬁn-embedded material using
a punch tool of 0.6 mm diameter. At least three complete cores
were used for RNA extraction. Standard H&E staining was
performed in order to ensure that removed tissue samples were
representative for the lesion.
RNA preparation
miRNA was prepared with the Recover All Total Nucleic Acid
Isolation Kit (Applied Biosystems, Darmstadt, Germany)
according to the kit protocol. In brief, tissue cylinders were
deparafﬁnised by xyleneeethanol extraction and subsequently
digested with proteinase K. Nucleic acids were bound to the
silica matrix of mini spin columns, washed, DNAse digested and
ﬁnally eluted with a volume of 60 ml elution buffer.
Reverse transcription
miRNAs were reverse transcribed with the TaqMan miRNA
Reverse Transcription Kit (Applied Biosystems, Darmstadt,
Germany), using 60 ng total RNA and pools of miRNA speciﬁc
stemloop primers (Megaplex RT-Primers Pool A and B, Applied
Biosystems). After reverse transcription, the cDNA was pream-
pliﬁed with Megaplex PreAmp Primers (Pool A and B) according
to the recommendations of the supplier (Applied Biosystems).
TaqMan low density arrays
miRNA analyses were performed using TaqMan MicroRNA
Array v2.0 (Applied Biosystems). Each sample was assayed with
an A & B card resulting in the analysis of a total of 667 miRNA.
Each miRNA was measured in duplicate.
Real-time PCR validation of single miRNAs
Key miRNAs from TaqMan low density arrays (TLDAs) were
selected for validation using real-time PCR. RNA from the
previous TLDAs was used to quantify miRNA levels of hsa-miR-
335-4395296, hsa-miR-139-3p-4395424 and hsa-miR-675-4395.
RNU48 served as endogenous control for normalisation. MiRNA
levels were compared with that of the normal adrenocortical
tissue. Quantitative reverse transcriptase PCR was done for each
sample in triplicate. The 12 ml real-time PCR mixture contained
5.25 ml cDNA (diluted 1:25), TaqMan Universal PCR master mix
(No AmpErase UNG) and 1 ml of TaqMan assay hsa-mir-675/
hsa-miR-335/hsa-miR-139-3p. The reaction was imitated at
958C for 10 min, followed by 40 cycles of 958C for 15 s, and 608C
for 1 min. The reaction was carried out using an Applied
Biosystem 7500 fast real-time PCR system (Applied Biosystems).
miRNA target prediction
The DIANA-microT algorithm was used to predict possible
target genes of differentially expressed miRNAs.
17 MicroT
identiﬁes miRNA targets by combining TargetScan and PicTar
predictions and has been reported to be the most selective
algorithm in a comparative study.
18
Statistical analysis
TaqMan low density arrays
Data obtained by the TLDAs was analysed using the StatMiner
3.0 software (Integromics, Madrid, Spain). Possible outliers in
eachbiologicalgroupwereidentiﬁedbycorrelationheatmaps,and
samples with a Pearson index >0.85 were discarded from further
analyses. The imputation was performed using the aggregation
method ‘median’ and the experimental factor ‘biological group’.
Detection thresholds were set to 35 and the best ﬁtting endoge-
nous control (RNU48-4373383 and MammU6-4395470) was
calculated with the Normﬁnder algorithm. A parameter t-test
(Limma) was applied for the relative quantiﬁcation.
Real-time PCR
Default threshold settings were used to determine the threshold
cycle data. The relative amount of each miRNA was calculated
using the comparative threshold (Ct) method with ΔCt¼Ct
(miRNA) Ct(RNU48). Relative quantiﬁcation of miRNA
expression was calculated with the 2
 ΔΔCt method (Applied
Biosystems User Bulletin No. 2 (P/N:4303859)). This method
(called the comparative CT method) is widely used to present
relative gene expression.
19 Differences between miRNA expres-
sion levels among two groups were evaluated using a t-test;
p-values <0.05 were considered signiﬁcant. Statistics were
performed with SPSS V.17.
RESULTS
Test cohort
TLDA analysis
Forthisstudyamicroarraytechniquewith667miRNAswasused
to identify signiﬁcantly (p<0.05) up- or down-regulated miRNAs
Table 1 Clinicopathological data of the four adrenocortical carcinomas in the test cohort
Adrenocortical
carcinomas
in test cohort Size Weight
Vascular
invasion
Capsular
invasion
Signiﬁcant
necrosis
High nuclear
grade
Increased mitotic
activity (>2 per
10 HPF) Metastasis
Case 1 14 cm Not known   + + + Not known
Case 2 17 cm 1078 g   + + + Not known
Case 3 18 cm Not known + + + + + Yes
Case 4 10 cm Not Known   + + + Yes
ACC, adrenocortical carcinoma; HPF, high power ﬁeld.
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syndrome, as well as ACCs and tissue from ACC metastases. In
the groups of ACCs and ACAs, several miRNAs with differen-
tial expression were identiﬁed. Figure 1 shows a series of
miRNAs identiﬁed as possibly useful for discriminating ACC
from ACA.
Normal adrenocortical tissue versus ACA associated with Cushing
syndrome
miRNA expression proﬁling showed 146 miRNAs to be signiﬁ-
cantly up-regulated and 17 miRNAs to be down-regulated in
ACAs associated (online supplement).
Normal adrenocortical tissue versus ACA associated with Conn
syndrome
miRNA expression proﬁling showed nine miRNAs to be signif-
icantly up-regulated and 47 miRNAs to be down-regulated
(online supplement).
Normal adrenocortical tissue versus ACC
MiRNA expression proﬁling showed 74 miRNAs to be signiﬁcantly
up-regulated and 62 miRNAs to be down-regulated (online
supplement).
Normal adrenocortical tissue versus tissue from ACC metastases
miRNA expression proﬁling showed 140 miRNAs to be signiﬁ-
cantly up-regulated and 22 miRNAs to be down-regulated
(online supplement).
ACA (Conn syndrome) versus ACC
miRNA expression proﬁling showed 38 miRNAs to be signiﬁ-
cantly up-regulated and 89 miRNAs to be down-regulated
(online supplement).
Adrenocortical adenoma (Cushing syndrome) versus adrenocortical
carcinoma
MiRNA expression proﬁling showed 159 miRNAs to be signiﬁ-
cantly up-regulated and 35 miRNAs to be down-regulated
(online supplement).
Figure 1 Unsupervised hierarchical cluster of
microRNAs (miRNAs) and adrenocortical
carcinoma (ACC) and adrenocortical adenoma
(ACA) samples. Each row shows an miRNA,
each column shows a sample. The miRNA tree
is on the right, the sample tree is on top. The
cluster shows miRNAs which separate ACCs
from ACAs. The colour scale at the upper right
illustrates the DDCt values of an miRNA across
ACC and ACA samples: red for a negative DDCt
value and green for a positive DDCt value. The
clustering is done on DDCt values, which
passed all ﬁltering criteria across all samples. C,
adrenocortical carcinoma; A, adrenocortical
adenoma.
Table 2 Expression levels of hsa-miR-139-3p-4395424, hsa-miR-675-4395192 and hsa-miR-335*-4395296 in normal, benign and malignant
adrenocortical lesions
miRNA Normal tissue (n[5)
Adenomas (n[9)
Carcinomas (n[4) Metastasis (n[3) Conn Cushing
hsa-miR-139-3p-4395424 7.0 7.6 7.3 7.3 6.4 8.1 6.0 6.7 7.1 6.8 5.6 8.0 6.3 4.3 9.7 10.8 9.7 10.6 9.8 11.3 7.3*
hsa-miR-675-4395192 6.7 5.9 6.8 5.8 5.8 8.8 6.0 7.8 6.4 6.3 5.8 5.0 7.1 4.3 10.8 11.6 10.1 10.5 10.5 10.2 7.5*
hsa-miR-335*-4395296 5.2 5.1 4.3 5.6 5.1 6.1 5.4 5.8 5.6 4.6 5.3 5.4 4.9 3.4 6.9 7.7 7.1 8.0 7.8 10.2 5.6*
Data presented in ΔCT of relative threshold cycles indicating fold changes over normal adrenal tissue. Low values indicate high levels of miRNA. Data derived from quantitative reverse
transcriptase PCR validation of miRNAs.
*miRNA expression levels of this case was beyond the expected range. The ampliﬁcation curves suggest an insufﬁcient RNU48 control. However, data was not deleted from statistics.
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Due to the large amount of signiﬁcantly differentially expressed
miRNAs, three key miRNAs were selected for further
validation by quantitative reverse transcriptase PCR: miRNA
hsa-miR-139-3p-4395424, hsa-miR-675-4395192 and hsa-miR-
335*-4395296. High values of relative threshold cycles indicate
low miRNA quantity, and data were normalised to RNU48
expression. Data from miRNA expression levels of one case with
metastatic tissue was beyond the expected range. Although the
ampliﬁcation curve suggested an insufﬁcient RNU48 control in
this particular experiment, we did not delete this data from
further statistical analysis.
Expression levels of miR-675
The lowest level of miR-675 was found in the group of ACCs
(10.76, SD 0.63), followed by metastatic tissue (9.43, SD 16.4),
ACAs associated with Conn syndrome (7.28, SD 1.31), normal
adrenocortical tissue (0.622, SD 0.49), and ACAs associated with
Cushing syndrome (5.71, 1.08). In the subgroup of ACCs and
ACAs, miR-675 expression of ACCs was distinctly different
from that of ACAs with a down-regulation of miR-675 in ACCs
of up to 20.42-fold. Compared to normal adrenal tissue, we
found down-regulation of miR-675 in ACCs up to 23.25-fold.
Tables 2 and 3 present data on miR-675 expression levels.
Figure 2 shows the distribution of expression levels among the
different subgroups.
Expression levels of miR-139-3p
The lowest level of miR-139-3p was found in the group of ACCs
(10.19, SD 0.56), followed by metastatic tissue (9.56, SD 1.92),
normal adrenocortical tissue (7.10, SD 0.43), ACAs associated
with Conn syndrome (6.98, SD 0.87), and ACAs associated with
Cushing syndrome (6.19, 1.35). In the subgroup of ACCs and
ACAs, miR-139-3p expression of ACCs was distinctly different
from that of ACAs with a down-regulation of miR-139-3p in
ACCs of up to 8.49-fold. Compared to normal adrenal tissue, we
found down-regulation of miR-139-3p in ACCs up to 11.34-fold.
Tables 2 and 3 present data on miR-139-3p expression levels.
Figure 2 shows the distribution of expression levels among the
different subgroups.
Expression levels of miR-335
The lowest level of miR-335 was found in the group of meta-
static tissue (7.87, SD 2.25), followed by ACCs (7.44, SD 0.54),
ACAs associated with Conn syndrome (5.73, SD 0.30), normal
adrenocortical tissue (5.05, SD 0.45), and ACAs associated with
Cushing syndrome (4.71, 0.79). In the subgroup of ACCs and
Table 3 Differential expression of hsa-miR-139-39, hsa-miR-675 and
hsa-miR-335 in normal adrenocortical tissue, adrenocortical adenomas
and adrenocortical carcinomas as well as metastasis
miRNA Fold change p Value
ACA compared to normal adrenocortical tissue; fold change normalised to normal
tissue
hsa-miR-139-3p 1.34Y 0.331
hsa-miR-335 1.10[ 0.772
hsa-miR-675 1.13[ 0.778
ACC compared to normal adrenocortical tissue; fold change normalised to normal
tissue
hsa-miR-139-3p 8.49Y <0.001
hsa-miR-335 5.25Y <0.001
hsa-miR-675 23.25Y <0.001
ACC compared to ACA; fold change normalised to ACA
hsa-miR-139-3p 11.34Y <0.001
hsa-miR-335 4.85Y <0.001
hsa-miR-675 20.42Y <0.001
Metastasis compared to ACA; fold change normalised to adrenocortical adenoma
hsa-miR-139-3p 6.09Y 0.008
hsa-miR-335 6.55Y 0.008
hsa-miR-675 8.12Y 0.010
List of key miRNAs with differential expression in normal adrenal tissue (n¼5),
adrenocortical adenomas (n¼9), adrenocortical carcinomas (n¼4) and metastasis (n¼3).
ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma.
Figure 2 (A) Expression levels of hsa-miR-139-3p-4395424 in
normal, benign and malignant adrenocortical lesions. Data derived
from quantitative real-time PCR and presented in ΔCT of relative threshold
cycles indicating fold changes over normal adrenal tissue. Low values
indicate high levels of miRNA. (B) Expression levels of hsa-miR-675-
4395192 in normal, benign and malignant adrenocortical lesions. Data
derived from quantitative real-time PCR and presented in ΔCT of relative
threshold cycles indicating fold changes over normal adrenal tissue. Low
values indicate high levels of miRNA. (C) Expression levels of hsa-miR-
335*-4395296 in normal, benign and malignant adrenocortical lesions.
Data derived from quantitative real-time PCR and presented in ΔCT of
relative threshold cycles indicating fold changes over normal adrenal
tissue. Low values indicate high levels of miRNA.
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from that of ACAs, with a down-regulation of miR-335 in ACCs
of up to 4.85-fold. Compared to normal adrenal tissue, we found
down-regulation of miR-335 in ACCs up to 5.25-fold. Tables 2
and 3 present data on miR-335 and miR-675 expression levels.
Figure 2 shows the distribution of expression levels among the
different subgroups.
Validation cohort
The three key miRNAs, hsa-miR-139-3p-4395424, hsa-miR-675-
4395192 and hsa-miR-335*-4395296, were selected for further
validation by quantitative reverse transcriptase PCR in a valida-
tion cohort of 15 primary adrenocortical lesions, all scored
according the Weiss score and one lung metastasis. Table 4
presents relevant clinicopathological data. Cases were sorted
according to increasing Weiss scores. The cut-off values of the
different miRNAs indicating a malignant behaviour were
derived from the test cohort and are as followed: miRNA 335,
>6; miRNA 139, >9; miRNA 675, >8.8.
miRNA-335
Regarding the expression levels of miRNA-335, all cases classi-
ﬁed as benign with a Weiss score of 0 showed values below the
cut-off of 6. Among the lesions with uncertain biological
behaviour (Weiss score 1e2), one case exhibited an expression
level above the cut-off. Lesions with a Weiss score of 3 to 5
revealed in three of ﬁve cases increased expression levels above
the cut-off value.
miRNA-139-3p
The expression levels of miRNA-139 in cases classiﬁed as benign
(Weiss score¼0) were lower than the cut-off value in ﬁve cases.
One case exhibited increased expression levels. Among the ﬁve
lesions with uncertain biological behaviour (Weiss score 1e2)
the cut-off value was not reached. All lesions with a Weiss score
of 3 to 5 lacked increased expression values. In one case data was
not available.
miRNA-675
All adrenocortical tumours with a Weiss score of 0 showed low
expression levels, not reaching above the cut-off value. One of
the lesions with uncertain behaviour (Weiss score 1) exhibited
values above the cut-off level. Of the ﬁve lesions with marked
increased Weiss scores including the metastasis, two specimens
showed expression levels above the cut off-level. Except for one
case, all specimens showed increased expression levels nearly
reaching the cut-off value.
DISCUSSION
The differential diagnosis of ACA from ACA is classically based
on a set of clinical and pathomorphological parameters.
However, taken alone, none of these parameters is sufﬁcient to
prove malignant behaviour. To overcome the problem, differing
scoring systems have been developed which are without excep-
tion rather complicated, time consuming and difﬁcult to repro-
duce.
20 21 Therefore novel markers allowing a more reliable
separation of benign from malignant adrenocortical lesions are
desirable. Molecular techniques such as miRNA analysis possess
signiﬁcant diagnostic potential.
22
miRNA arrays can be used to differentiate different types of
tissue such as non-neoplastic pancreatic tissue from human
pancreatic adenocarcinoma
23 or non-neoplastic prostatic tissue
from prostatic adenocarcinoma.
24 In addition, various studies
have been successful in correlating miRNA expression levels
with survival time in different cancer types, such as pancreatic
carcinoma
24 25 and colorectal cancer.
26 A previous study of our
group found miRNA expression analysis to be helpful for the
differential diagnosis of various types of polyps of the color-
ectum.
27 In endocrine pathology, miRNA analysis has been
established as a useful tool in thyroid tumour pathology. Using
speciﬁc sets of miRNAs, various benign and malignant
tumour entities can be associated with characteristic up- or
down-regulation patterns.
5e10
Concerning adrenocortical pathology, a study on 22 ACAs and
33 ACCs using DNA array analysis managed to accurately
classify benign and malignant tumours and offered novel prog-
nostic information derived from gene expression patterns.
11 Very
recently, Soon et al
9 published a study on 22 ACAs and 27 ACCs,
suggesting the diagnostic and prognostic value of even single
miRNAs. miRNA analysis thus seems to facilitate separation of
adrenocortical neoplasm.
In this study we analysed 667 miRNAs in order to further
strengthen the foundation for the miRNA based classiﬁcation
and differentiation of normal adrenocortical tissue, ACAs, ACCs
and ACC metastasis. In a second step we validated expression
data of three highly signiﬁcantly altered single key miRNAs
using real-time PCR. A third step was conducted with
Table 4 miRNA expression values in the validation cohort
Tumour size Tumour weight Weiss score Metastasis miR-335 cut-off >6 miR-139-3p cut-off >9 miR-675 cut-off >8.8
Case 1 2 cm 3 0 No 5.399 8.247 4.462
Case 2 2 cm 3 0 No 5.678 7.544 5.322
Case 3 3 cm 7 g 0 No 4.820 9.165 6.318
Case 4 3 cm 3 0 No 5.359 7.661 6.805
Case 5 3 cm 3 0 No 3.131 4.928 6.046
Case 6 4.5 cm 40 g 0 No 4.532 7.131 5.653
Case 7 2.4 cm 3 1 No 5.299 6.523 5.527
Case 8 3 cm 34 g 1 No 4.611 6.504 6.665
Case 9 5 cm 3 1 No 4.796 7.997 9.326
Case 10 6 cm 3 2 No 6.217 3.909 3.970
Case 11 9 cm 180 g 2 No 4.124 7.084 7.720
Case 12 4.5 cm 3 3 No 5.959 3 3.727
Case 13 9.3 cm 180 g 4 No 7.683 5.242 8.813
Case 14 8 cm 110 g 5 No 7.321 6.386 8.749
Case 15 14 cm 500 g 5 Yes (lung) 5.319 7.011 9.023
Case 16 33 Metastasis Yes (lung, liver) 6.728 8.764 8.059
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study was performed with parafﬁn-embedded tissue which was
recently shown to be suitable for miRNA arrays.
28 Our study
reveals up to 146 statistically signiﬁcantly differentially
expressed miRNAs in the various subgroups analysed. Thus this
study conﬁrms the power of molecular proﬁling as a novel
diagnostic tool for the diagnosis of adrenocortical tumours. Our
results show that TLDA based assessment can assist in sepa-
rating malignant from benign lesions. Due to the huge amount
of differentially expressed miRNAs, we focused on three single
key miRNAs with the most signiﬁcantly differential expression:
miRNA 139-3p, miRNA 675 and miRNA 335. Each of these
miRNAs allowed separation of ACCs from ACAs in the test
cohort. We observed distinctly different miRNA expression
levels, with up to 23.25-fold down-regulation of miR-675 in
ACC compared to normal adrenocortical tissue and up to 20.42-
fold down-regulation of miR-675 in ACC compared to ACA. Our
results are in accordance with those of Soon et al,
16 who found
23 miRNAs to be differentially expressed between ACA and
ACC. Among these are miRNA 335 and miRNA195, which our
study also identiﬁed as diagnostically valuable miRNAs.
We were aware that the test cohort needed further conﬁr-
mation using a validation cohort. The validation cohort
consisted of adrenocortical tumours with known Weiss score,
including six benign tumours without any histopathological
criteria proposed by Weiss (score 0). In fact, none of the three
selected miRNAs correlated directly with the Weiss score.
However, miRNA-335 and miRNA-675 show a potential diag-
nostic value in predicting the biological behaviour of adreno-
cortical tumours. In the subgroup containing cases with
a marked increased Weiss score (score $3) or histologically
proven metastasis, miRNA-335 and miRNA-675 levels were
up-regulated in three of ﬁve and in three of ﬁve adrenocortical
tumours, respectively. In contrast, miRNA-139 did not prove to
be a useful tool for identifying the potential biological behaviour
of adrenocortical lesions. MiRNA-139 was up-regulated in
several ACAs (Weiss score¼0) of the validation cohort and lacked
up-regulation in cases with malignant potential (Weiss score
$3). Using a cut-off value derived from the test cohort, analysis
of miR-335 expression levels identiﬁed correctly three of ﬁve
cases with highly probable malignant course. Moreover miR-335
and 675 levels were markedly increased in two cases, with
a Weiss score of 1 and 2, respectively. It is tempting to speculate
that these cases may exhibit a malignant course. Unfortunately
no long term follow-up data exist for these two patients.
Especially in the grey zone of tumours with indeterminate
malignant potential (Weiss score 1e2), miRNA levels show wide
variations, indicating different genetic background alterations in
these tumours.
Furthermore, this study conﬁrms that miRNAs extracted
from formalin-ﬁxed and parafﬁn-embedded material can be
successfully and reliably applied in routine diagnostic pathology.
There seems to be a large number of signiﬁcantly expressed
miRNAs in adrenal tumour pathology, depending on the nature
Table 5 Potential targets for miRNA-675, miR-139-3p and miR-335
Ensemble gene ID miTG Score Precision Gene description
miR-139-3p
GLI4 ENSG00000181638 12.00 0.83 Zinc ﬁnger protein GLI4 (Krueppel-related zinc ﬁnger protein 4)
ZFP41 ENSG00000181638 12.00 0.83 Zinc ﬁnger protein GLI4 (Krueppel-related zinc ﬁnger protein 4)
FN3K ENSG00000167363 12.00 0.83 Fructosamine-3-kinase
C10orf39 ENSG00000188385 9.00 0.4 CDNA FLJ45017 ﬁs
MLC1 ENSG00000100427 8.00 0.4 Membrane protein MLC1
BARHL1 ENSG00000125492 8.00 0.4 BarH-like one homoeobox protein.
miR-675
GLI4 ENSG00000181638 18.00 0.98 Zinc ﬁnger protein GLI4
ZFP41 ENSG00000181638 18.00 0.98 Zinc ﬁnger protein GLI4
MGAM ENSG00000179087 9.00 0.83 Maltase-glucoamylase
miR-335
NEBL ENSG00000078114 12.42 0.18 Nebulette (actin-binding Z-disk protein)
C8orf44 ENSG00000213865 9.66 0.18 Putative uncharacterised protein C8orf44
SEC14L5 ENSG00000103184 9.42 0.18 SEC14-like 5
PRDM2 ENSG00000116731 9.42 0.18 PR domain zinc ﬁnger protein 2 (PR domain-containing protein 2) (retinoblastoma
protein-interacting zinc ﬁnger protein) (zinc ﬁnger protein RIZ) (MTE-binding protein)
(MTB-ZF) (GATA-3-binding protein G3B)
PLEKHK1 ENSG00000182010 9.42 0.18 Pleckstrin homology domain containing
KPNA6 ENSG00000025800 9.07 0.18 Importin subunit a-7 (karyopherin subunit a-6).
TNFAIP1 ENSG00000109079 9.00 0.18 BTB/POZ domain-containing protein TNFAIP1 (tumour necrosis factor)
ONECUT2 ENSG00000119547 9.00 0.18 One cut domain family member 2
UNC5D ENSG00000119547 9.00 0.18 One cut domain family member 2 (transcription factor ONECUT-2) (OC-2).
UNC5D ENSG00000156687 9.00 0.18 Netrin receptor UNC5D precursor (Unc-5 homologue D) (Unc-5 homologue 4).
MMAA ENSG00000151611 9.00 0.18 Methylmalonic aciduria type A protein
Ensemble gene ID: provides a link to the Ensembl page of the gene, which contains information on sequence, alignments, protein products and links to much more information.
Total miTG score: the ﬁnal prediction score. A higher miTG score corresponds to a higher possibility of being a real target. A non-strict (default) threshold is set at score 7.3 and a strict
threshold at score 19.
Take-home messages
< MicroRNAs (miRNAs) possess a tremendous potential as
diagnostic biomarkers in surgical pathology.
< Up to 159 miRNAs were up-regulated and up to 89 were
down-regulated in adrenocortical carcinomas (ACCs)
compared to adrenocortical adenomas (ACAs).
< miR-335 and miR-675 expression levels helped to distinguish
ACAs from ACCs and may help in identifying adrenocortical
tumours with malignant behaviour.
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resulting in either Conn or Cushing syndrome. The DIANA-
micro T algorithm was used to predict possible target genes of
the identiﬁed key miRNAs (table 5).
Interestingly, miRNA-675 and miRNA-139-3p share
a common target gene (GLI4). However, this basic study was
not designed to analyse possible functional effects of single
miRNAs. Further experiments are in progress to elucidate the
association of miRNA regulation/deregulation with already
identiﬁed or putative target genes. We are aware that at
this point of time little is known about the potential
functional relevance of the identiﬁed miRNA in adrenocortical
tumours.
In conclusion, this study provides a rich source of information
about miRNAs that are differentially expressed in normal,
benign and malignant adrenocortical tumours. In contrast to the
study of Soon et al,
16 we found a much larger number of
miRNAs to be signiﬁcantly differentiated between ACA and
ACC. However, due to overlapping miRNA expression values in
the validation cohort, a single miRNA value is not capable of
clearly separating benign from malignant adrenocortical lesions.
Nevertheless, using proposed cut-off values, expression analysis
of miR-675 and miR-335 seems to offer highly valuable infor-
mation about the potential subsequent malignant behaviour of
lesions with indeterminate malignancy.
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